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Available online 19 August 2014Abstract Human embryonic stem cells (hESCs) are capable of extensive self-renewal and expansion and can differentiate
into any somatic tissue, making them useful for regenerative medicine applications. Allogeneic transplantation of hESC-derived
tissues from results in immunological rejection absent adjunctive immunosuppression. The goal of our study was to generate a
universal pluripotent stem cell source by nucleofecting a mutated human leukocyte antigen G (mHLA-G) gene into hESCs using
the PiggyBac transposon. We successfully generated stable mHLA-G(EF1α)-hESC lines using chEF1α promoter system that stably
expressed mHLA-G protein during prolonged undifferentiated proliferation andin differentiated embryoid bodies as well as
teratomas. Morphology, karyotype, and telomerase activity of mHLA-G expressing hESC were normal. Immunofluorescence
staining and flow cytometry analysis revealed persistent expression of pluripotent markers, OCT-3/4 and SSEA-4, in
undifferentiated mHLA-G(EF1α)-hESC. Nucleofected hESC formed teratomas and when directed to differentiate into epidermal
precursors, expressed high levels of mHLA-G and keratinocyte markers K14 and CD29. Natural killer cell cytotoxicity assays
demonstrated a significant decrease in lysis of mHLA-G(EF1a)-hESC targets relative to control cells. Similar results were
obtained with mHLA-G(EF1α)-hESC-derived epidermal progenitors (hEEP). One way mixed T lymphocyte reactions unveiled
that mHLA-G(EF1a)-hESC and -hEEP restrained the proliferative activity of mixed T lymphocytes. We conclude that
heterologous expression of mHLA-G decreases immunogenicity of hESCs and their epidermal differentiated derivatives.
© 2014 Published by Elsevier B.V.Introduction
Embryonic stem cells (ESCs) are pluripotent stem cells derived
from the inner cell mass of blastocysts. They represent an ideal⁎ Corresponding author at: Escape Therapeutics, Inc., 5941 Optical
Court, Suite 218A2, San Jose, CA 95138, USA. Fax: +408 960 3822.
E-mail address: basil@escapetherapeutics.com (B.M. Hantash).
http://dx.doi.org/10.1016/j.scr.2014.08.004
1873-5061/© 2014 Published by Elsevier B.V.tissue source for cell replacement therapy due to their
potential for limitless self-renewal while retaining pluripotency
and a normal karyotype, as well as for differentiation to all cell
types of the body upon proper induction (Thomson et al., 1998;
Reubinoff et al., 2000; Itskovitz-Eldor et al., 2000). Recent
studies suggest that allogeneic ESCs and their differentiated
progeny are immunogenic and do not inhibit immune responses
during direct or indirect antigen presentation, leading to their
343Mutated HLA-G expression reduces hESC immunogenicityacute rejection in a xenogeneic setting (Swijnenburg et al.,
2005, 2008). Thus, immunogenicity represents a substantial
clinical challenge for realizing the clinical potential of hESC.
Rejection occurs due to allelic differences between
donor and recipient at polymorphic loci across 3 classes of
histocompatibility antigens: ABO blood-group, major histo-
compatibility complex (MHC), and minor histocompatibility
(mHA) (Bradley et al., 2002). ABO mismatch can result in
hyperacute rejection. The presence of mHA and/or MHC
mismatches will activate indirect T cell allorecognition,
eventually leading to acute or chronic rejection. To overcome
these challenges, some investigators have a proposed creation
of a human leukocyte antigen (HLA)-typed hESC bank (Taylor,
2001); however, a recent study reported that a single mHA
locus mismatch can result in graft rejection (Robertson et al.,
2007). Others have suggested replacing immunosuppressives
withmesenchymal stem cells, but initial studies failed to show
a benefit when coinjected with ESC (Puymirat et al., 2009).
Derivation of patient-specific induced pluripotent stem cells
(iPSCs) via somatic cell nuclear reprogramming has also been
proposed (Jaenisch and Young, 2008). However, this tech-
nique suffers from substantial cost limitations and technical
hurdles such as faulty or low rates of reprogramming and
genomic instability. Thus, there remains an urgent unmet
need for novel strategies that confer tolerance to hESC
without these limitations.
HLA-G is a non-classical HLA class I molecule exclusively
expressed in placental trophoblast cells and thought to play a
key role inmaternal-fetal immune tolerance (Apps et al., 2008).
Since it was first discovered in 1987 (Geraghty et al., 1987), 7
isoforms have been identified, including 4 membrane-bound
(HLA-G1 to -G4) and 3 soluble proteins (HLA-G5 to -G7)
(Kirszenbaum et al., 1994; Ishitani and Geraghty, 1992;
Carosella et al., 1996). Full-length β2 microglobulin (β2m)
associated HLA-G1 and its soluble counterpart HLA-G5 cause a
direct inhibitory effect on proliferation and cytolytic function
of peripheral blood natural killer (NK) cells and cytotoxic T
lymphocytes (Rouas-Freiss et al., 1997a, b; Riteau et al.,
2001; Bahri et al., 2006; Lemaoult et al., 2007; Caumartin
et al., 2007), maturation and function of dendritic cells
(Horuzsko et al., 2001), and alloproliferative responses of
CD4+ T cells (Riteau et al., 1999).
The goal of our study was to generate a universal
pluripotent stem cell source that can be transplanted into
patients with limited complications in the absence of
adjunctive immunosuppression, HLA matching, or autolo-
gous sourcing. We assessed the effects of heterologous
HLA-G expression on the immunogenicity of hESCs and their
derivatives using in vitro and in vivo systems.Materials and methods
DNA constructs
PiggyBac transposase cDNA was custom synthesized by GeneArt
(Invitrogen, Grand Island, NY). To generate helper plasmids,
transposase cDNAs were cloned in pBluescript (Agilent
Technologies, Santa Clara, CA) downstream of a human
phosphoglycerate kinase (PGK) promoter (Singer-Sam et al.,
1984) and upstream of an SV40 polyadenylation signal sequence
(Fig. S1A). Commercial PiggyBac transposon vector wasobtained from System Biosciences (Mountain View, CA).
Mutated HLA-G1 (mHLA-G1) cDNA was modified at the
endoplasmic reticulum (ER) recycling motif and 3′-untrans-
lated region (3′UTR) microRNA binding sites (Fig. S1C), then
cloned downstream of the multiple cloning site of PiggyBac
transposon vector. Expression cassettes contained the
murine stem cell virus (pMSCV) promoter driving mHLA-G1
and human elongation factor-1 alpha (hEF1α) promoter
driving copGFP (Fig. S1B). To generate EF1α-mHLA-G1,
pMSCV promoter was cut out and Chinese hamster EF1α
promoter was cloned from CHO cells and inserted upstream
of mHLA-G1 (Fig. S1B). For nucleofection, all plasmids were
prepared with an EndoFree Plasmid Maxprep kit (Qiagen,
Valencia, CA).hESC line and culture conditions
We minimized the impact of ABO mismatch by using H1 hESC,
previously shown to carry type O alleles, O101 and O201
(Metallo et al., 2010). H1 hESC line (Thomson et al., 1998) was
obtained from WiCell Research Institute, Inc. (Madison, WI).
hESCs were grown on matrigel (BD Biosciences, Bedford,
MA)-coated culture dishes in mTeSR-1 medium (Stem Cell
Technologies, Vancouver, Canada) at 37 °C in a humidified
incubator with 5% CO2. Media were refreshed daily. For
expansion, hESCs were enzymatically passaged with 2 mg/ml
dispase (Stem Cell Technologies). hESC lines were karyotyped
by standard G-banding performed by Applied Stem Cell, Inc
(Menlo Park, CA).
Embryoid bodies (EB) were generated by treatment of hESC
cultures with 1 mg/ml dispase until colonies were detached
from the substrate. Individual aggregates were then transferred
to low attachment 10 cm bacterial culture dishes (BD Biosci-
ences, San Jose, CA) and grown in DMEM-F12 supplemented
with 20% KOSR, 100 mM non-essential amino acids, 2 mM
GlutaMAX, 100 mM β-mercaptoethanol (Invitrogen,Grand Is-
land, NY).Mediawere refreshed every other day. Differentiated
EB were dissociated by trypsinization for 3 min at 37 °C with 1–
3 ml of 0.05% trypsin solution (Invitrogen) and constant shaking.
To differentiate hESC into epidermal progenitor cells
(hEEP), hESC colonies were grown for 4 d on matrigel
in mTeSR-1 medium before switching to differentiation
medium, which contained DMEM/F12 with 1× N2 supple-
ment (Invitrogen), 1 μM all-trans retinoic acid (Sigma-
Aldrich, St. Louis, MO), and 25 ng/ml BMP-4 (Peprotech,
Rocky Hill, NJ). After 7 d, differentiated cells were
detached with 2 mg/ml dispase and separated into small
cell clumps, then plated onto gelatin (Millipore, Billerica,
MA)-coated plates in defined keratinocyte serum-freemedium
(DSFM, Invitrogen) changed every other day. hESCs were
allowed to differentiate using this method for 3–4 weeks
(Metallo et al., 2010).Teratoma formation
To generate teratomas, 5 × 106 hESCs were injected subcu-
taneously into 3-month-old NOD SCID IL2 receptor γ chain
knockout (NSG) mice (The Jackson Laboratory, Bar Harbor,
ME). Teratomas were allowed to develop for 6–8 weeks,
excised, fixed in neutral buffered formalin, and analyzed
344 L. Zhao et al.histologically by trained pathologists at Transgenic Center of
Stanford Cancer Institute.Gene transfer
Prior to dissociation and nucleofection, hESCs were treated
for 1 h with 10 mM ROCK inhibitor Y-27632 (Sigma-Aldrich)
to reduce dissociation-induced apoptosis and increase
cloning efficiency (Watanabe et al., 2007; Lacoste et al.,
2009). hESCs were then dissociated in accutase (Innovative
Cell Technologies. Inc, San Diego, CA) at 37 °C for 5–10 min,
washed in mTeSR-1 medium with ROCK inhibitor, and
resuspended in solution V or L (Lonza, Walkersville, MD).
Helper and transposon plasmids were added to the cell
suspension, and nucleofection was performed with program
setting B-016 or A-023 per manufacturer's protocol (Lonza).
hESCs were then plated in mTeSR-1 medium supplemented
with 10 mM ROCK inhibitor at 5 × 105 cells per matrigel-
coated 6 cm dish. Culture media were changed to mTeSR-1
medium without ROCK inhibitor 20–24 h after nucleofection
and cultured for 3 d. At day 4, hESC colonies were selected
using 300 ng/ml puromycin (Sigma) for 4 d and 600 ng/ml
puromycin for an additional 2 d. Transient nucleofection
efficiency was evaluated by flow cytometry 24 h after
nucleofection. Stable GFP+ colony count was based on
microscopic observation.Semi-quantitative RT-PCR
Isolation of total RNA from cells and reverse transcriptase
reactions were described previously (Zhao et al., 2010). Briefly,
harvested cells were homogenized using cell shredders (Qiagen,
Valencia, CA). Lysatewas collected and total RNAwas retrieved
using a RNA isolation mini kit (Qiagen). cDNA was synthesized
from 2 μg of purified total RNA using reverse transcriptase
(SuperScript III kit, Invitrogen). Semi-quantitative PCR was
performed in a Bio-Rad DNA Engine thermal cycler as described
(Zhao et al., 2012a). Primer sequences (Table 1) were
determined using Primer 3 (http://www-genome.wi.mit.
edu). 15 μl of each PCR product was detected by ethidium
bromide gel electrophoresis using a 1% agarose gel run in
triplicate, then analyzed using Alpha Innotech's AlphaEase®
FC Software: FluorChem HD2 version 6.0.2. Intensities were
measured using the spot-denso tool. Relative expression level
was taken as the ratio of expression of each gene of interest
over β-actin.Table 1 Primer sequences (all from 5′–3′).
Genes Primer forward sequence
mHLA-G CAGACTGCTGAGAGGCTAC
GFP ATGGAGAGCGACGAGAGC
K14 GGCCTGCTGAGATCAAAGAC
TAp63 CCTTACATCCAGCGTTTCGT
ΔNp63 AAGTAGATTCATATTGTAAGGGT
GAPDH ATGCTGGCGCTGAGTACGTCAntibodies
Monoclonal antibodies to HLA-G (MEM-G/9 and 4H84) and
HLA-E (MEM-E/06), and polyclonal antibodies to cytokeratin
14 (K14) and Oct3/4 were purchased from Abcam (Cambridge,
MA). Anti-HLA-A/B/C (Bu8) antibodies were obtained from
Novus Biological (Littleton, CO) while anti-HLA-DR/DP/DQ
(WR18), anti-β2m, and anti-β-actin antibodies were ob-
tained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Antibodies against CD29 and SSEA-4 were purchased
from BioLegend (San Diego, CA). All secondary and isotype
control antibodies were purchased from Abcam.Total protein isolation and Western blots
Cells were washed twice with ice-cold PBS and protein was
extracted using radioimmune precipitation assay (RIPA)
buffer containing 50 mM Tris–HCl (pH 8), 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), and protease inhibitors. After centrifugation
at 9000 g at 4 °C for 20 min, supernatants were collected
and protein concentration was determined using the BCA
protein assay kit (Pierce Biotechnology, Rockford, IL) with
BSA serving as the standard.
Thirty μg of total protein from undifferentiated hESCs and
EBs were separated in 12% SDS-PAGE. Samples were supple-
mented with 6× Laemli buffer and heated for 5 min at 95 °C
before being subjected to 12% SDS-PAGE. Proteins were then
electroblotted onto nitrocellulose membranes (Hybond;
Amersham, Pittsburgh, PA). Membranes were blocked by
incubation with PBS containing 0.2% Tween 20, 3% non-fat
dry milk, and 1% BSA overnight at 4 °C, then probed with
anti-β2m or anti-β-actin antibodies (loading control) for 2 h at
room temperature and washed 3 times in PBS containing 0.2%
Tween 20. Membranes were subsequently incubated for 1 h
at room temperature with goat anti-mouse IgG conjugated
with alkaline phosphatase (Invitrogen), washed thoroughly,
and signal detected by BCIP/NBT color development system
(Promega, Madison, WI).Immunofluorescence and flow cytometry
Cell immunostaining was performed as previously described
(Zhao et al., 2012b). Briefly, hESC clones grown on matrigel-
coated chamber slides (Nalge Nunc International corp,
Naperville, IL) were washed with cold PBS once. Cells were
then blocked with 10% goat serum and 3% BSA/PBS forPrimer reverse sequence
GGCAGACTGCTCTGCTTC
GGCGATGGGGGTCTTGAAG
CATACTTGGTGCGGAAGTCA
TCAATGGGCTGAACTGAACA
CTCG AGTCTGGGCATTGTTTTCCA
CAGGGGTGCTAAGCAGTTGGT
345Mutated HLA-G expression reduces hESC immunogenicity20 min at 4 °C, followed by staining with primary antibodies
diluted to 5–20 μg/ml in blocking buffer for 60 min at 4 °C.
After washing, cells were fixed with 1% paraformaldehyde
(PFA) for 10 min, washed and subsequently stained with
secondary antibodies conjugated with DyLight® 550 (Abcam)
for 30 min at 4 °C. Control aliquots were stained with
isotype-matched IgG to evaluate non-specific binding. Cells
were mounted with anti-fade media containing DAPI (Vector
Laboratories, Burlingame, CA). Slides were observed under a
Leica CTR6500 fluorescent microscope (Leica Microsystems,
Bannockburn, IL). In order to detect intracellular protein
expression, cells were fixed with 4% PFA for 20 min at room
temperature and permeabilized with 0.3% Triton X-100 in
blocking buffer for 40 min at room temperature, then
stained with primary antibodies.
For flow cytometry, 1 × 106 hESC or EB-derived cells were
harvested and washed twice with cold PBS. After staining
with primary and secondary antibodies conjugated with
SureLight® Allophycocyanin, cells were washed 3 times and
resuspended in PBS. Data was acquired with FACSCalibur (BD
Biosciences) and analyzed with CellQuest (BD Biosciences).
The cutoff level defined by the isotype control antibody was
set to b5%.
Magnetic-activated cell sorting (MACS)
MACS was performed according to protocols described by
Miltenyi Biotech, Inc. (Auburn, CA). Briefly, 1 × 106 differ-
entiated hESCs were labeled with 2 μg anti-CD29 antibody
in 100 μl PBS, incubated for 1 h at 4 °C, and then washed
with PBS. Cells were centrifuged at 300 g for 10 min. The
supernatant was aspirated and cells resuspended in 50 μl of
MACS buffer. Twenty μl of the goat anti-mouse IgG1
conjugated microbeads were added to cells and incubated
at 4 °C for 30 min. Cells were then washed, collected, and
resuspended in 500 μl of buffer. MACS columns attached to
the magnetic sorter were first rinsed with 3 ml of buffer and
eluent discarded. Cells were then applied to the columns,
washed with 3 ml of buffer 3 times and eluent was
discarded. Columns were then removed from the magnetic
sorter and 5 ml of buffer was immediately applied. The
eluent was collected in a fresh centrifuge tube and labeled
as CD29+ cells. Sorted cells were cultured in gelatin-coated
10 cm cell culture dishes fed with DSFM medium which
was changed every other day. At 70% confluence, they
were harvested with 0.05% trypsin/EDTA and labeled as
passage 0.
NK cytotoxicity assay
Cytotoxicity assays were performed using a CytoTox96 non-
radioactive cytotoxicity assay kit (Promega, Madison, WI) as
previously described (Zhao et al., 2012a). Briefly, effector
cells (NK-92) were mixed with 2.5 × 103 (hESC) or 1.0 × 103
(hEEP) target cells at various effector:target cell ratios in
U-bottom 96 well plates (Corning, Tewksbury, MA). After
incubation for 4 h at 37 °C in a humidified 5% CO2 incubator,
50 μl of supernatants was collected to determine lactate
dehyrogenase (LDH) release. Target cell spontaneous and
maximal LDH release and effector cell spontaneous LDH
release were determined by incubating cells in mediumalone. Each assay was performed in triplicate and the %
specific lysis was determined as follows: (experimental
release − effector spontaneous release − target spontane-
ous release/target maximum release − target spontaneous
release) × 100. In all experiments, spontaneous release was
less than 10% of maximum release.
Mixed T lymphocyte reaction
Human peripheral blood mononuclear cells (PBMCs) were
purchased from Astarte Biologics (Redmond, WA). PBMCs
were thawed according to the manufacturer's protocol
(Astarte Biologics) and immediately used in the assays.
Proliferation of human peripheral blood mixed T lympho-
cytes was measured using a CellTiter 96® AQueous one
solution cell proliferation assay kit (Promega). Mitomycin
(Sigma-Aldrich) treated hESC or hHEEP were dissociated to
single cell suspensions and seeded at 1 × 105 per well in
50 μl of CTL-test medium (Cellular Technology Limited,
Shaker Heights, OH) in 96-well plates. The same number of
human PBMCs in 50 μl of CTL-test medium was added to
96-well plates. The cell mixture was incubated at 37 °C for
5 d. Mixed T lymphocyte cell proliferation was determined
by adding 20 μl of CellTiter solution to each well and
incubated at 37 °C for 4 h in a humidified, 5% CO2 incubator.
MTS absorbance was recorded at 490 nm using a 96-well
plate reader. Each assay was performed in triplicate and
proliferation rate was determined as follows: (OD value of
mixed cells − OD value of hESC or hEEP alone/OD value of
PBMC alone).
Results
Generation of a stable mHLA-G expressing hESC line
It has been demonstrated that humanized PiggyBac
transposase increased genome integration efficiency by
10-fold versus the original insert PiggyBac transposase
(Lacoste et al., 2009). We constructed a PiggyBac helper
plasmid, pBS-TA, which introduced human PGK driven
PiggyBac transposase (Fig. S1A). mHLA-G-GFP-expressing
donor plasmids (Fig. S1B) contain human EF1α promoter
driving copGFP and puromycin resistance fusion cassette and
Chinese hamster EF1α or pMSCV promoter driving mHLA-G
open reading frame and 3′UTR. Both promoter systems were
shown to enable high-level transgene expression in stably
transfected ESC (Chan et al., 2008; Grez et al., 1990). The 2
cassettes were flanked by a 5′- and 3′-terminal repeat, two
minimal sequences which are necessary and sufficient for
transposition (Li et al., 2005).
HLA-G gene is composed of 8 exons and 7 introns with a
stop codon at exon 6, a 1.4 kb 5′-promoter region, and a 3′
UTR (Castelli et al., 2010). Variations in the 3′UTR of HLA-G
locus are associated with HLA-G expression levels. Several
studies demonstrated a 14-bp polymorphism in exon 8
(non-coding region) which was expressed at a significantly
lower level than the corresponding HLA-G mRNA isoforms
with the 14-bp sequence deleted (Rousseau et al., 2003;
Hviid et al., 2003). It has been reported that microRNAs have
allele-specific targeting for single-nucleotide polymorphism
of 3′UTR to decrease HLA-G mRNA expression (Castelli et al.,
346 L. Zhao et al.2010, 2009). HLA-G possesses a short cytoplasmic tail
(6 amino acids, RKKSSD) due to a stop codon in exon 6
(Geraghty et al., 1987). Park et al. found that assembled
HLA-G complexes were recycled between the ER and
cis-Golgi via a dilysine motif in the truncated cytoplasmic
tail of HLA-G (Park et al., 2001). In order to enhance HLA-G
mRNA expression and stability and HLA-G protein cell
surface expression, we designed a novel HLA-G construct
(mHLA-G) (Fig. S1C) by combining 3 modifications: 1) mutation
of HLA-G's ER retrieval motif (K334A/K335A) to increase cell
surface levels, 2) elimination of 14-bp sequence in exon 8, and
3) mutation of 3′UTR microRNA binding sites to increase mRNA
stability. Fig. 1A shows 42–47% efficiency which was obtained
using solution L or V and nucleofector setting A23 or B16
(p b 0.05).
To determine genome integration efficiency, stable colonies
were isolated by gradually increasing puromycin concentration.
GFP-puro vector without helper plasmid was used as a control in
these experiments. GFP expression in control cells was rapidly
lost, and all cells died after 3 d in puromycin. After 5 d in
puromycin, significantlymoreGFP+ colonieswere obtainedwith
solution V and nucleofector setting B16 (436 ± 52 GFP+ colonies
per 5 × 105 transfected cells) compared to other parameter
combinations (Fig. 1B). In addition, increasing cells from5 × 105
to 10 × 105 per reaction increased genome integration efficien-
cy (106 ± 44 vs 356 ± 37 GFP+ colonies) (Fig. 1C). Expressing the
transposase driven by EF1α promoter via 6 μg of DNA per
1 × 106 cells, transposase/transposon ratio of 1:2, solution V
and nucleofector setting B16 resulted in optimumnucleofection
efficiency.0
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Figure 1 Optimization of hESC nucleofection. (A) % of GFP+ c
accutase-dissociated H1 hESC in solution V or L combined with nucleofe
10 d after nucleofection of accutase-dissociated H1 hESC in solution V
colonies generated 10 d after nucleofection of accutase-dissociated
(D) GFP expression of nucleofected GFP-H1 hESC 1, 3, 7, and 10 d posWe generated 17 GFP-hESC, 14 mHLA-G(EF1a)-GFP-hESC,
and 13 mHLA-G(pMSCV)-GFP-hESC lines from the expanded
colonies which showed strong GFP expression. Four of these
lines from each group were characterized more extensively in
further experiments. The results revealed both GFP and mHLA-
Gwhichwere highly expressed inmHLA-G(EF1a)-GFP-hESC lines
(Figs. 2A & B). mHLA-G transcripts or proteins were rarely
detected in mHLA-G(pMSCV)-GFP-hESC line (Figs. 2A & C), even
though GFP expression was high in these cells. Flow cytometry
studies confirmed that nearly 93% of mHLA-G(EF1a)-GFP-hESC
cells were positive when stained with anti-HLA-G antibody
(4H84) (Fig. 3A). Only 5% of mHLA-G(pMSCV)-GFP-hESC cells
showed weak staining, a similar level as wildtype hESC and
GFP-hESC cells (Fig. 3A).Transgene hESC lines maintain their
hESC characteristics
We next explored whether PiggyBac-mediated mHLA-G
nucleofection resulted in any detectable effects on
pluripotency. Immunostaining against OCT-3/4 and SSEA-4
showed mHLA-G(EF1a)-GFP-hESC expressed similar levels as
undifferentiated hESC colonies (Fig. S2A) and wild type cells
(data not shown). FACS confirmed that transgene hESC lines
exhibited high levels of SEEA-4 and OCT-3/4 expression
(99% and 92–93%, respectively), similar to wildtype H1-hESC
(Fig. S2B & S2C).
At 14 d post-differentiation, transgenic EB were GFP+
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Figure 2 mHLA-G and GFP expression in nucleofected hESC lines. (A) RT-PCR analysis of HLA-G and GFP mRNA expression in mHLA-G(EF1a)-GFP-hESC and mHLA-G(pMSCV)-GFP-hESC
lines. β-Actin served as a template loading control. Immunofluorescence staining of HLA-G in transfected mHLA-G(EF1a)-GFP-hESC (B) and mHLA-G(pMSCV)-GFP-hESC (C). GFP (top
left), phase contrast (top right), HLA-G (bottom left), DAPI (bottom right).
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348 L. Zhao et al.dissociation, FACS analysis showed that the level of emitted
green fluorescence declined slightly compared to undifferen-
tiated ESCs (Fig. S3B). Cytogenetic analysis of mHLA-G(EF1a)-
GFP-hESC demonstrated retention of normal female karyo-
type (46, XX) (Fig. S3C) with no apparent abnormalities
compared to wild type. All implant sites of mHLA-G(EF1a)-
GFP-hESC resulted in teratoma formation within 6–8 weeks
with 100% efficiency, similar to GFP-hESC clones. Histological
examination demonstrated tissue structures representing all 3
germ layers (Fig. S3D) and HLA-G+ staining (Fig. S3E).
To assess transgene silencing, stable nucleofectants were
passaged 15 times without further selection and the propor-
tion of cells without HLA-G was quantitated by FACS analysis.
Fig. S4 shows that later passage clones showed HLA-G levels
within 1–4% of earlier passage clones. Similar results were
obtained with 3 GFP-hESC clones and 2 other mHLA-G(EF1a)-
GFP-hESC clones.Effect of HLA-G transgene expression on cell surface
HLA class I and II protein levels
To determine if mHLA-G transgene expression influences
cell surface HLA class I and II protein levels, flow cytometryTable 2 Surface expression profile of HLA and β2M in wildtype,
Antibody Wildtype GFP
% reactivity
(Mean ± SEM)
MFI ratio
(Mean ± SEM)
% react
(Mean ±
HLA-A, B, C 98.3 ± 0.5 123.5 ± 9.1 97.3 ± 0
HLA-E 2.4 ± 0.4 0.8 ± 0.1 3.7 ± 1
HLA-G 8.0 ± 1.0 1.0 ± 0 7.0 ± 0
HLA-DP, DQ, DR 29.7 ± 3.2 3.7 ± 0.9 28.0 ± 2
β2M 99 364 98.7 ± 0
⁎ p ≤ 0.01.was performed with non-permeabilized hESCs. The results
showed that non-transfected H1-hESCs express high levels
of HLA-A, -B, -C, and low levels of HLA class II proteins
(Fig. S5). HLA-G and -E were not expressed on the cell
surface of H1-hESCs (Fig. S5 & Table 2). Transfection of GFP
and/or mHLA-G did not change surface expression levels of
HLA classes I and II, except for increasing HLA-G expression
in mHLA-G(EF1a)-GFP-hESC (Fig. S5 & Table 2). HLA class Ia
expression decreased in differentiated EBs (Table. 2). Both
the % reactivity of HLA class II proteins and their fluorescent
density declined in EB relative to undifferentiated hESC
(Table 3). Flow cytometry and Western blotting demonstrat-
ed total and surface expression of β2m which was reduced in
differentiated EB cells (Fig. S6).Differentiation of mHLA-G(EF1a)-GFP-hESC into
epidermal progenitor cells
Wenext differentiatedmHLA-G(EF1a)-GFP-hESC into epidermal
lineage via a 7 d treatment with 1 μM retinoic acid and
25 ng/ml BMP4 followed by 14 d of cultivation in DSFM, at
which point we began observing an epidermal sheet structure
(Fig. 4A, upper panel). At 4 weeks of culturing, cuboidal celland GFP- and mHLA-G(EF1a)-GFP-hESC.
mHLA-G(EF1a)-GFP
ivity
SEM)
MFI ratio
(Mean ± SEM)
% reactivity
(Mean ± SEM)
MFI ratio
(Mean ± SEM)
.6 117.3 ± 10.9 98.3 ± 0.4 132.1 ± 9.2
.0 0.9 ± 0.1 4.0 ± 0.6 0.8 ± 0.1
.7 1.0 ± 0 58.6 ± 6.2 ⁎ 7.1 ± 1.4 ⁎
.0 3.5 ± 0.3 29.3 ± 1.9 3.6 ± 0.2
.3 298 ± 32 99.0 ± 0 357 ± 51
Table 3 Surface expression profile of HLA and β2M in undifferentiated hESC and EB.
Antibody HLA-A, B, C HLA-DQ, DR, DP β2M
% reactivity
(Mean ± SEM)
MFI ratio
(Mean ± SEM)
% reactivity
(Mean ± SEM)
MFI ratio
(Mean ± SEM)
% reactivity
(Mean ± SEM)
MFI ratio
(Mean ± SEM)
Undiff hESC 98.7 ± 0.2 218 ± 28 ⁎ 43.3 ± 3.8 ⁎ 4.9 ± 0.5 ⁎ 98.7 ± 0.2 315 ± 23 ⁎
EB 7 d 98.3 ± 0.3 153 ± 12 ⁎ 27.0 ± 2.3 ⁎ 2.3 ± 0.2 ⁎ 98.3 ± 0.3 153 ± 12 ⁎
EB 14 d 97.0 ± 0.8 120 ± 2 ⁎ 11.0 ± 0.0 ⁎ 1.1 ± 0.0 ⁎ 97.3 ± 0.7 78 ± 7 ⁎
⁎ p ≤ 0.05.
349Mutated HLA-G expression reduces hESC immunogenicitymorphology was apparent and semi-quantitative RT-PCR indicat-
ed that K14, Tap63, and ΔNp63 were expressed (Figs. 4C & D).
Fluorescent microscopy showed that GFP intensity
decreased during epidermal differentiation (Fig. 4A, lower
panel). FACS confirmed only 53–90% of hESC-derived
hEEP emitted green fluorescence and fluorescent intensity
was reduced relative to undifferentiated hESC (Fig. S7).
RT-PCR illustrated the relative expression of GFP mRNA
which decreased early during differentiation and continued
to gradually decline in GFP-hESC lines. With mHLA-G(EF1a)-
GFP-hESC, transcription of GFP was steady until 21 d post-
differentiation and slightly decreased thereafter. In contrast,
HLA-G expression was relatively stable during epidermal
differentiation (Fig. 4B).
The subculture of CD29 MACS sorted differentiated
colonies enriched for K14+ populations. FACS analysis
showed that 92% of mHLA-G(EF1a)-GFP-hEEPs expressed
K14 after MACS sorting versus only 31% in unsorted hEEP
or 4% in undifferentiated hESC (Fig. 5A). Immunostaining
confirmed that purified mHLA-G(EF1a)-GFP-hEEPs highly
express K14 and CD29 (Fig. 5B). FACS showed that 93–97% of
mHLA-G(EF1a)-GFP-hEEPs were positive for HLA-G vs 0–5% of
wild type and GFP-hEEPs (Fig. 5C).
mHLA-G(EF1a)-GFP-hESCs and their epidermal
derivatives are immunosuppressive in vitro
Cytotoxicity assays showed that the % lysis of mHLA-G(EF1a)-
GFP-hESC targets by NK-92 cells was significantly decreased
to 8 ± 2% compared to 23 ± 1% for GFP control cells at 30:1
E:T (Fig. 6A). Similar results were obtained at 10:1 E:T.
mHLA-G(EF1a)-GFP-hEEP inhibited NK cytotoxic lysis relative
to control cells (4 ± 1% vs 17 ± 4% at E:T 10:1 and 11 ± 3% vs
47 ± 9% at E:T 30:1) (Fig. 6B).
Alloproliferation assays showed that mHLA-G(EF1a)-GFP-
hESC restrained the proliferative activity of mixed T lympho-
cytes relative to control hESC (proliferation index 1.8 ± 0.1 vs
2.1 ± 0.1, p b 0.002) (Fig. 7A). mHLA-G(EF1a)-GFP-hEEP
exhibited the same inhibitory effect on PBMC growth.
The proliferation index of mHLA-G(EF1a)-GFP-hEEP group
(1.4 ± 0.1) was statistically significantly less than the GFP-
hEEP group (1.7 ± 0.1, p b 0.05) (Fig. 7B).
Discussion
In this study, we generated for the first time immune tolerant
hESC by nucleofecting HLA-G gene via a high expression
promoter system as would be required for human regenerative
medicine applications. Our study compared 3 viral and cellularpromoters previously shown to drive robust transgene expres-
sion in hESC (Chan et al., 2008; Ran et al.; Oue et al.). hESC
reporter lines generated with CHEF1α and hEF1α showed
high and stable transgene expression without silencing. With
CHEF1α, heterelogous HLA-G expression remained strong
even under differentiation pressure and teratoma formation;
however, GFP expression driven by hEF1α was diminished
during hESC differentiation. This discrepancy may be due to
76% homology between CHEF1α and hEF1α (Chan et al., 2008).
The mechanism by which CHEF1α promoter augments gene
expression is currently unknown but may involve transcrip-
tional enhancers, insulator elements, scaffold/matrix attach-
ment regions, or transcription termination elements (Chan et
al., 2008). Although MSCV promoter showed selectively high
activity in murine hESC and in Purkinje cells of transgenic
mice, it remained sensitive to transcriptional silencing in
other cell types (Oue et al.; Osborne et al., 1999; Swindle
et al., 2004). MSCV resulted in very few drug-selectable
stable nucleofectants in our experiments suggesting it may be
silenced in hESC.
Nucleofection is a method to introduce plasmid DNA
into ESC with significantly greater efficiency than electro-
poration or virus-mediated (lentivirus, retrovirus) delivery
(Lakshmipathy et al., 2004; Aslan et al., 2006; Aluigi et al.,
2006). Nucleofection achieved ~60% transient expression
efficiency in hESC (Siemen et al., 2005), a similar level as that
achieved in our study. To overcome concerns about irreversible
genetic alterations, we used the PiggyBac transposon system
which allows fully reversible gene delivery. In this regard,
PiggyBac is not only superior to viral vectors which mediate
irreversible gene integration but also to previously describe
transposases including Sleeping Beauty based systems that can
be excised but leave mutations in the host genome upon
excision (Yates and Daley, 2006). To minimize the impact of
ABO mismatch, we used H1 hESC since they have previously
been shown to carry type O alleles (Chen et al., 2008). H1 cells
were shown to be RhD+ (Lu et al., 2008), the sameRh phenotype
of 93–99% of the world's population. Although RhD+ status
prevents their use to derive universal blood (O−), the fact that
RhD antigen expression is confined to erythroid tissues should
theoretically allow O+ H1 ESC to remain a viable source
to derive all non-erythroid tissue types. The limitation of
universal erythroid-lineage derivation will be circumvented
by engineering mHLA-G into O− hESC when this phenotype
becomes available.
For hESC-based cell technologies to be useful for human
clinical applications, it is important to culture cells in a
serum-free and murine feeder-free environment before
transferring cells to patients. To provide a more uniform
microenvironment during differentiation, we eliminated EB
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Figure 4 Differentiation of mHLA-G(EF1a)-GFP-hESC into epidermal progenitor cells. (A) Undifferentiated mHLA-G(EF1a)-
GFP-hESC were treated with 1 μM RA and 25 ng/ml BMP4 for 7 d and cultured in DSFM for additional 28 d. Images were taken at
serial time points of differentiation under phase contrast (upper panel) and fluorescent microscopy (lower panel). (B) RT-PCR analysis
of GFP and mHLA-G mRNA expression during transgenic hESC epidermal differentiation. RNA was isolated from differentiated cells
harvested at serial time points during differentiation. All PCR except for GAPDH (25 cycles) was run for 30 cycles. (C and D)
Quantitative PCR analysis of epidermal marker expression during hESC epidermal differentiation.
350 L. Zhao et al.formation and directly induced differentiation of hESC colonies
cultivated on matrigel with RA and BMP-4 and by subculturing
on gelatin in DSFM for 28 d. RA-induced differentiation of hESCnot only offers an efficient means of generating keratinocytes
and rapidly eliminating Oct-4+ undifferentiated hESC from
culture, it also allows for differentiation in defined medium.
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Figure 5 MACS sorting with anti-CD29 antibody significantly
enhanced purity of hEEP. (A) FACS analysis of K14 expression in
undifferentiated hESC as well as differentiated unsorted and
sorted hEEP. Cells were stained with anti-K14 antibody and
analyzed by FACS. Histograms show specific antibodies staining
(black) overlay with an isotype-matched control antibody (gray).
(B) Immunofluorescence staining of sorted mHLA-G(EF1a)-GFP-
hEEP showed that cells highly express keratinocyte markers K14
and CD29 (left panel). Corresponding images showed cell nucleus
stained by DAPI (right panel). (C) FACS analysis of mHLA-G
expression in wildtype and transfected hEEP. Cells were stained
by anti-HLA-G antibodies (4H84) (upper panel) or MEM-G/09
(lower panel) and analyzed by FACS. Histograms show specific
(black) or isotype-matched control (gray) antibody staining.
351Mutated HLA-G expression reduces hESC immunogenicityOne of the most significant problems plaguing keratinocyte
derivation from hESC is the presence of other cell types in
the culture. In this study, we generated differentiated cell
cultures in which 31% of the cells expressed K14 after 5 weeks
of differentiation. Upon serial subcultivation, the number of
K14 expressing cells in the population steadily decreased over4 passages. This effect could be the result of differences in the
growth rates between K14+ and K14− cells, dedifferentiation of
K14 expressing cells, loss of adherence, or cell death (Ji et al.,
2006). To obtain pure populations of hEEP, differentiated hESCs
were sorted for CD29, a surfacemarker of epidermal stem cells.
Previous studies found that CD29 (β1 integrin) regulates
keratinocyte differentiation and proliferation (Brakebusch et
al., 2000; Zhu et al., 1999), and localizes to the basal layer of
both interfollicular epidermis and outer root sheath of the hair
follicle bulge, the purported epidermal stem cell reservoir
(Jiang et al.). Subculture of CD29 sorted differentiated
colonies dramatically enriched for K14+ keratinocytes.
Skin is the largest organ of the body and acts as a protective
barrier to harmful bacteria as well as thermal insults and
chemical agents that can cause acute trauma and chronic
wounds. Cell-based regenerative strategies using autologous
keratinocytes have been used for the treatment of large burns
(Lemaitre et al., 2011). However, this technique has several
disadvantages such as donor site morbidity as well as a long
waiting times for in vitro expansion of keratinocytes that leave
patients at risk of dehydration and infection. Thus, clinical
grade ‘off-the-shelf’ keratinocytes are required to avoid
the treatment delays seen in autologous transplantation.
Immune-tolerant epidermal stem cells derived from hESCs,
such as those described in our study, hold great promise for
allogeneic transplantation for the treatment of skin burns and
wounds.
In this report, we demonstrated that undifferentiated
hESCs expressed moderate levels of HLA-class Ia, no class Ib,
and low levels of class II molecules on the cell surface.
HLA class Ia processing and presentation are required for
effective T cell recognition and impact graft rejection. This
finding supported the idea that undifferentiated hESCs
are immunogenic and subject to allorejection after trans-
plantation into wild-type, fully HLA-mismatched recipients
(Swijnenburg et al., 2005; Wu et al., 2008; Nussbaum et al.,
2007). Furthermore, during EB differentiation, HLA class Ia and
II molecule levels decreased significantly. This may be due
to the decreased levels of β2m protein, as pluripotent stem
cells (Shef-1, NT2 and MSUH-002 cell lines) previously shown to
express low to no β2M light chain also showed limited cell
surface levels of trimeric HLA class I (Suarez-Alvarez et al.).
Derivation of iPSC by nuclear reprogramming of patient-
specific cells (Carvajal-Vergara et al., 2010; Narsinh et al.,
2011) brought much enthusiasm for the possibility of patient
specific cell therapy without immune rejection. However, the
assumption that differentiated cells derived from patient
specific iPSC can be transplanted in the same patient without
immune rejection has been disputed by studies performed by
Zhao et al. (2011). This study demonstrated that teratomas
formed from iPSCs derived from C57BL/6 (B6) mouse are
immunogenic in syngeneic B6 recipient. On the other hand,
autologous ESC derived teratomas did not show any evidence
of immune rejection in B6 mice. Furthermore, although initial
studies indicated that human iPSCs are similar to hESCs
(Guenther et al., 2010; Yu et al., 2007), recent studies
indicate the presence of considerable differences with regard
to in vitro differentiation potential (Feng et al., 2010), gene
expression (Chin et al., 2009), and DNA methylation (Doi et
al., 2009). Thus, generation of immune tolerant hESCs and
their derivatives is critical for the advancement of allogenic
transplantation.
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Figure 7 Mixed T lymphocyte reaction with transgenic hESC and hEEP. 1 × 105 effector cells (PBMC) were mixed with
mitomycin C treated hESC (A) or hEEP (B) target cells in U-bottom 96 well plates and incubated for 5 d at 37 °C. T lymphocyte
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352 L. Zhao et al.Our study demonstrated a proof of concept on engineering
immune tolerant hESCs that could be used as a pluripotent
universal cell source. Nonetheless, it remains to be determined
whether HLA-G transgenic hESC and their epidermal derivatives
are immune-tolerant in vivo. Humanized mice harboring
human immune system cells (Brehm and Shultz, 2012) have
recently been developed and may serve as useful tools to assess
the immunogenicity of mHLA-G transgenic hESC and hEEP in
vivo.
In conclusion, we successfully demonstrated that mHLA-G1
ransgenic hESCs and their epidermal derivatives inhibited
NK cytotoxic lysis and proliferation of mixed PBMC. These
findings suggest heterologous expression of a silencing-
resistant form of HLA-G1 in hESCs using the non-viral
PiggyBac system that may allow for the creation of the
first universal pluripotent stem cell line with the potentialof persistent avoidance of immunological rejection in the
allotransplantation setting.Acknowledgments
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